Velphoro was well tolerated with long-term use*1
GI adverse events were mild to moderate, and resolved without intervention1

Adverse events occurring in >5% of patients during the 52-week clinical study1,2:
-
Diarrhea (24%): The majority of diarrhea events were mild and transient, occurred soon after initiation of treatment, and resolved1
See time to onset
-
Discolored feces (16%): Discolored feces is expected with an iron-containing product1
-
Nausea (10%): Incidences were reported during the first 6 months, but diminished over time2


Velphoro is selective, with few drug or metabolic interactions
Velphoro is a powerful, selective phosphate binder that doesn't bind to vitamins A, D, E, K, or folic acid, as sevelamer does.1,3
Patients taking Velphoro require no additional monitoring for iron management
The iron in Velphoro is not absorbed. Nearly all of it binds to phosphate1
No additional monitoring of iron indices needed1
Velphoro has no contraindications, and does not contribute to iron overload syndrome1